MIR-16 mediates trastuzumab and lapatinib response in ERBB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.

Venturutti L1, Cordo Russo RI, Rivas MA, Mercogliano MF, Izzo F, Oakley RH, Pereyra MG, De Martino M, Proietti CJ, Yankilevich P, Roa JC, Guzmán P, Cortese E, Allemand DH, Huang TH, Charreau EH, Cidlowski JA, Schillaci R, Elizalde PV2.